Cognitive Behavioral Therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?

Helen M. Spencer, Martina Mcmenamin, Richard Emsley, Douglas Turkington, Graham Dunn, Anthony P. Morrison, Alison Brabban, Paul Hutton, Robert Dudley

Research output: Contribution to journalArticlepeer-review

Abstract

This study investigated the effect of “dose” and the components of Cognitive Behavioral Therapy (CBT) on treatment effects. It is a secondary analysis of the ACTION (Assessment of Cognitive Therapy Instead of Neuroleptics) trial which investigated CBT for people with schizophrenia spectrum disorders that chose not to take antipsychotic medication. Using instrumental variable methods, we found a “dose-response” such that each CBT session attended, reduced the primary outcome measure (the PANSS total score) by approximately 0.6 points (95% CI −1.20 to −0.06, p = 0.031). This suggests that length of therapy is important for those that receive CBT in the absence of antipsychotic medication. Secondly, using principal stratification we examined the process variables that modified treatment effects. Findings revealed that those who received a longitudinal formulation in the first 4 sessions of CBT had poorer treatment effects than those who did not, however this finding was not statistically significant (95% CI −37.244, 6.677, p = 0.173). However, it is important to note that these findings were evident in an exploratory analysis with a small sample. Future larger scale studies are needed to help understand components of effective treatment.
Original languageEnglish
JournalSchizophrenia Research
Early online date12 Jul 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Dive into the research topics of 'Cognitive Behavioral Therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?'. Together they form a unique fingerprint.

Cite this